0QLR.L - Novartis AG

LSE - LSE Delayed price. Currency in CHF
78.76
+1.76 (+2.29%)
At close: 4:19PM BST
Stock chart is not supported by your current browser
Previous close77.00
Open78.86
Bid0.00 x 0
Ask0.00 x 0
Day's range78.55 - 79.08
52-week range78.55 - 79.08
Volume596,781
Avg. volumeN/A
Market cap201.137B
Beta0.54
PE ratio (TTM)23.09
EPS (TTM)3.41
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Novartis’s Q2 2018 Estimates: Innovative Medicines Business
    Market Realist5 hours ago

    Novartis’s Q2 2018 Estimates: Innovative Medicines Business

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic, oncology, immunology, dermatology, respiratory, neuroscience, and established products. The chart below compares revenues for its Innovative Medicines business since the first quarter of 2017. Novartis’s (NVS) Innovative Medicines business is expected to report second-quarter growth in its operating revenues. This segment’s second-quarter growth is expected to be partially offset by lower sales of ophthalmology products and established medicines.

  • Segment-Wise Expectations for Novartis in Q2 2018
    Market Realist6 hours ago

    Segment-Wise Expectations for Novartis in Q2 2018

    Analysts expect Novartis’s (NVS) second-quarter revenues to increase ~6.1% to ~$12.99 billion following growth in its operating revenues across all three segments. The chart below compares the company’s actual quarterly revenues since the first quarter of 2017 and analysts’ estimates for the second quarter.

  • Expectations from Novartis’s Q2 2018 Earnings
    Market Realist8 hours ago

    Expectations from Novartis’s Q2 2018 Earnings

    Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.

  • FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%
    Market Realist14 hours ago

    FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%

    On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.

  • Is a Surprise in the Cards for Novartis in Q2 Earnings?
    Zacks14 hours ago

    Is a Surprise in the Cards for Novartis in Q2 Earnings?

    Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft
    Zacks14 hours ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft

  • The Wall Street Journal3 days ago

    [$$] Novartis Played Down Ties to Trump Lawyer Michael Cohen, Report Says

    Novartis AG made misleading statements playing down its 2017 relationship with President Donald Trump’s then-personal lawyer, according to a report released Friday by Democratic senators that shed new light on the company’s consulting contract with the lawyer, Michael Cohen. The report also reveals Mr. Cohen’s advocacy for another pharmaceutical company, one the report says has ties to an investment firm associated with Viktor Vekselberg, a wealthy Russian businessman now under U.S. sanctions. The $1.2 million consulting deal with Novartis came to light in May. Then the Switzerland-based drug company said it hired Mr. Cohen for insight into how “the Trump administration might approach U.S. health-care policy matters,” but that executives realized from their first meeting with him in March 2017 that he wouldn’t be helpful and stopped engaging with him.

  • Novartis Looks to Exit Antibacterial, Antiviral Program
    Zacks3 days ago

    Novartis Looks to Exit Antibacterial, Antiviral Program

    Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

  • Associated Press3 days ago

    Dems: Novartis deal with Cohen sought access to policymakers

    WASHINGTON (AP) — President Donald Trump's former personal lawyer, Michael Cohen, was in frequent contact with top officials of pharmaceutical giant Novartis as part of a $1.2 million consulting deal, and the Swiss-based company expected him to provide access to Trump administration policymakers, according to a report Friday by a group of Senate Democrats.

  • Novartis Account of Cohen Connection Assailed by U.S. Senators
    Bloomberg3 days ago

    Novartis Account of Cohen Connection Assailed by U.S. Senators

    U.S. Senate Democrats are questioning the truthfulness of Novartis AG’s account of its relationship with Donald Trump’s lawyer, saying its ties were deeper than the Swiss drugmaker has acknowledged. An investigation by the lawmakers provided excerpts from emails and other documents to show that the business arrangement between Michael Cohen and the company extended longer than Novartis has previously said. While the pharma giant said it decided not to engage further with Cohen after an initial meeting with him in early 2017, Trump’s personal fixer and then-Chief Executive Officer Joe Jimenez had multiple discussions over the next six months, according to the report released Friday.

  • Reuters4 days ago

    Novartis disputes U.S. senators' report on Cohen contract

    Novartis (NOVN.S) on Friday disputed a report from Democratic U.S. senators that concluded the Swiss drugmaker misled the public about its $1.2 million (914,076.78 pounds)contract with a former attorney for President Donald Trump. "We disagree with the report's conclusion that we issued a misleading public statement regarding the extent of our engagement with (Michael) Cohen," Novartis said of the report compiled by staff of Sen. Ron Wyden, from Oregon, and other minority party lawmakers. Among other things, the document contends that former Novartis Chief Executive Joe Jimenez had "multiple additional communications" with Cohen including e-mails and phone calls.

  • JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?
    Zacks4 days ago

    JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings?

    With Johnson & Johnson (JNJ) and Novartis AG (NVS) scheduled to report on Jul 17 and Jul 18, respectively, this may be a good time to figure out which of these is a better stock.

  • Cohen's Novartis Work Was Broader Than Reported, Democrats Say
    Bloomberg4 days ago

    Cohen's Novartis Work Was Broader Than Reported, Democrats Say

    Michael Cohen, longtime lawyer to President Donald Trump, not only took money from companies looking for insight into the new administration but pressed one of his clients to take up an investment opportunity to benefit Russian-linked Columbus Nova, another client. The disclosure, contained in a report produced by an investigation led by Senate Democrats, shows that Cohen promoted the investment in a company backed by Columbus Nova to Novartis AG. Novartis in turn offered a list of ideas on how to lower drug prices and sent it to Cohen, who promised to pass it along to the administration, according to the report.

  • Cohen Pitched Novartis Russia-Tied Investment, Democrats Say
    Bloomberg4 days ago

    Cohen Pitched Novartis Russia-Tied Investment, Democrats Say

    Michael Cohen, longtime lawyer to President Donald Trump, not only took money from companies looking for insight into the new administration but also pressed one of his clients to take up an investment opportunity to benefit Russian-linked Columbus Nova, another client. The disclosure, contained in a report produced by an investigation led by Senate Democrats, shows that Cohen promoted the investment in a company backed by Columbus Nova to Novartis AG. Novartis in turn offered a list of ideas on how to lower drug prices and sent it to Cohen, who promised to pass it along to the administration, according to the report.

  • Better Know Biotech: Regenxbio Inc.
    Motley Fool4 days ago

    Better Know Biotech: Regenxbio Inc.

    This gene therapy company has big catalysts approaching that could cause shares to pop or drop.

  • Superbugs Win Another Round as Big Pharma Leaves Antibiotics
    Bloomberg4 days ago

    Superbugs Win Another Round as Big Pharma Leaves Antibiotics

    Novartis AG is the latest drug giant to end antibacterial and antiviral research, joining the likes of AstraZeneca Plc, Sanofi, Allergan Plc and Medicines Co. GlaxoSmithKline Plc has put some antibiotics assets under review. Sales of new antibiotics are too low for big pharma to recoup its investments, and public measures to encourage more activity aren’t moving the needle. “We’re at a point now where resistance is moving a lot faster than our ability to provide new antibiotics.

  • Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area
    Bloomberg5 days ago

    Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area

    Novartis AG will shut down its antibacterial and antiviral research operations in the San Francisco Bay area and cut about 140 jobs, joining other pharmaceutical giants that have pulled out of the field in recent years. The exit is part of the Swiss drugmaker’s move to narrow its R&D focus under its new chief executive officer. Vas Narasimhan, who took over in February, said in an interview last month that his priorities include gene-therapy programs for cancer treatment, neuroscience and ophthalmology.

  • Removing the Hidden Obstacle Holding Back New Cancer Therapies
    Bloomberg5 days ago

    Removing the Hidden Obstacle Holding Back New Cancer Therapies

    Technologies like CRISPR that alter a patient’s DNA to treat disease are transforming medicine, but a little-known roadblock could slow the revolution. To insert new, potentially life-saving DNA inside the body’s cells, doctors typically rely on bespoke viruses manufactured in a few specialty labs that are frequently backlogged amid surging demand. “It’s not the sexy part of the process, but it’s really important to get right,’’ said Fred Ramsdell, vice president of research at the Parker Institute for Cancer Immunotherapy in San Francisco.

  • Drugmakers Cancel Price Hikes After California Law Takes Effect
    Bloomberg6 days ago

    Drugmakers Cancel Price Hikes After California Law Takes Effect

    A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.

  • What Analysts Recommend for Novartis Stock
    Market Realist8 days ago

    What Analysts Recommend for Novartis Stock

    In Q2 2018, analysts expect Novartis’s revenue to fall 7.6% YoY (year-over-year) to $13.2 billion from $12.2 billion. They expect Novartis to see EPS of $1.32, and its net income margin to decrease YoY to 22.8% from 23.3%, mainly due to higher SG&A (selling, general, and administrative) and R&D (research and development) expenses.

  • Analyzing Novartis’s Alcon over Recent Quarters
    Market Realist10 days ago

    Analyzing Novartis’s Alcon over Recent Quarters

    Alcon, Novartis’s (NVS) eyecare business, includes surgical and vision care products. In Q1 2018, Alcon revenue grew 12% YoY (year-over-year) to ~$1.8 billion from ~$1.6 billion, driven by 7% operating revenue growth and boosted by 5% due to foreign exchange. The chart below shows Alcon’s revenue since Q1 2017.

  • Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
    Zacks11 days ago

    Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

    Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

  • How Novartis Stock Did in June
    Market Realist11 days ago

    How Novartis Stock Did in June

    Novartis (NVS), which specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products, reports its business under three segments: Innovative Medicines, Sandoz (generics), and Alcon (eye care). The chart below shows Novartis’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.

  • How Novartis’s Sandoz Has Performed
    Market Realist11 days ago

    How Novartis’s Sandoz Has Performed

    Novartis’s (NVS) Sandoz, a market leader in differentiated generics, saw its revenue grow 4% YoY (year-over-year) to ~$2.5 billion in Q1 2018, boosted by 8% due to foreign exchange and offset by a 4% decline in operating revenue. The chart below shows Sandoz’s quarterly revenue since Q1 2017.

  • A Look at Novartis’s Innovative Medicines Business
    Market Realist11 days ago

    A Look at Novartis’s Innovative Medicines Business

    Novartis’s (NVS) Innovative Medicines business, which includes prescription pharmaceutical and oncology products, contributed over 66% of Novartis’s total revenue in Q1 2018. Its revenue grew 12% YoY (year-over-year) to $8.4 billion.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes